# EDGAR Filing Document

**Accession Number:** 0001527728
**File Stem:** 0001731122-23-000353
**Filing Date:** 2023-3
**Character Count:** 7578
**Document Hash:** 11f5a7c0f4a75cb411812358e3e74911
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001731122-23-000353.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001731122-23-000353

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enochian Biosciences Inc
- **CENTRAL INDEX KEY:** 0001527728
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 452259340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38758
- **FILM NUMBER:** 23725898

**BUSINESS ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067
- **BUSINESS PHONE:** 45 39179840

**MAIL ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DanDrit Biotech USA, Inc.
- **DATE OF NAME CHANGE:** 20140214

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Putnam Hills Corp.
- **DATE OF NAME CHANGE:** 20110810

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** **SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 13, 2023**

**<u>ENOCHIAN BIOSCIENCES INC.</u>** (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Delaware** | &nbsp;&nbsp;**000-54478** | &nbsp;&nbsp;**45-2559340** |
| &nbsp;&nbsp;(State or other jurisdiction | &nbsp;&nbsp;(Commission File Number) | &nbsp;&nbsp;(I.R.S. Employer |
| &nbsp;&nbsp;of incorporation) |  | &nbsp;&nbsp;Identification No.) |

---

**1927 Paseo Rancho Castilla**

**Los Angeles, CA 90032** (Address of principal executive offices)

**<u>+1 (305) 918-1980</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of Each Class</u>** | **<u>Trading Symbol</u>** | **<u>Name of Each Exchange on Which Registered</u>** |
| Common Stock, par value $0.0001 per share | ENOB | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

On March 13, 2023, Enochian Biosciences Inc. (the "<u>Company</u>") issued a press release. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>"), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits:

---

| | | |
|:---|:---|:---|
| **EXHIBIT NO.** | **DESCRIPTION** | **LOCATION** |
| 99.1 | [Press Release dated March 13, 2023](e4488_ex99-1.htm) | Furnished herewith |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **ENOCHIAN BIOSCIENCES, INC.** | **ENOCHIAN BIOSCIENCES, INC.** |
| By: | /s/ Luisa Puche |
|  | Name: Luisa Puche<br> Title: Chief Financial Officer |

---

Date: March 13, 2023

## Exhibit 99.1

**Exhibit 99.1**

**Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements**

LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)*.* Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7<sup>th</sup> and March 9<sup>th</sup>, 2023, respectively.

"I am very pleased that the Company is once again compliant with the NASDAQ listing requirements. We have turned another page towards a promising future," said Gregg Alton, former long-time General Counsel and Chief Compliance Officer and, later, Interim CEO of Gilead Sciences, and Lead Independent Board Member of Enochian BioSciences.

Dr. Mark Dybul, CEO of the Company, said, "Returning to full compliance is a significant accomplishment. Despite challenges, the science remains strong and encouraging. I look forward to the Company advancing its novel technology to possibly treat several solid tumors with relatively poor life expectancy from pre-clinical to clinical phase potentially by early 2024."

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as "believes," "plans," "expects," "aims," "intends," "potential," or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Enochian BioSciences' most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Enochian BioSciences Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Source: Enochian Biosciences Inc.